Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426 for Advanced Clear Cell RCC

By Brian Rini, MD, FASCO, Christopher Wallis, MD, PhD, FRCSC - Last Updated: June 5, 2023

Brian Rini, MD, FASCO, Vanderbilt-Ingram Cancer Center, and Christopher Wallis, MD, PhD, University of Toronto, discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data available for pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma.

View more ASCO 2023 videos.

Advertisement
Advertisement